Johnson & Johnson JNJ
NYSE JNJ
$276.17 +3.84 (+1.41%)
At close: Nov 6, 2026 · 4:00 PM EST

Johnson & Johnson (JNJ) Net Income towards Common Stockholders (2009 - 2026)

Updated

Johnson & Johnson's Net Income towards Common Stockholders came in at $210 million for Q3 2026, down 95.9% from $5.15 billion a year earlier and down 96.2% from the prior quarter.

Analysis

Johnson & Johnson (JNJ) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends

Over the trailing twelve months to Sep 27, 2026, Johnson & Johnson reported Net Income towards Common Stockholders of $16.1 billion, down 35.9% year-over-year; for FY2025, it was $26.8 billion, up 90.6% from FY2024.

  • Net Income towards Common Stockholders carries a four-year compound annual growth rate of 16.2% (FY2021 to FY2025).
  • Going back by year, Net Income towards Common Stockholders was $14.07 billion in FY2024 (-60.0%), $35.15 billion in FY2023 (+95.9%), $17.94 billion in FY2022 and $14.71 billion in FY2021.
  • The Q3 2026 figure represents the lowest quarterly Net Income towards Common Stockholders since Q1 2023.
  • Year-over-year, Net Income towards Common Stockholders has declined for three consecutive quarters, with growth averaging 29.1% over the last eight quarters.
  • The fastest year-over-year change in Net Income towards Common Stockholders over five years came in Q1 2025 (growth of 237.9%), and the weakest in Q3 2026 (a decline of 95.9%).
  • Business Quant data shows JNJ's Net Income towards Common Stockholders at $5.53 billion (Q2 2026), $5.24 billion (Q1 2026) and $5.12 billion (Q4 2025) in the three quarters before Q3 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Eli Lilly 1,224.11 Bn 1,197.72 Bn 20.46 Bn 6.45 Bn
2 Johnson & Johnson 665.34 Bn 585.20 Bn 17.30 Bn 210.00 Mn
3 AbbVie 515.72 Bn 483.73 Bn 13.12 Bn 4.22 Bn
4 Merck 362.64 Bn 325.58 Bn 13.19 Bn 5.07 Bn
5 Novartis Ag 315.51 Bn 288.75 Bn - -
6 Astrazeneca 289.26 Bn 263.15 Bn 13.26 Bn 3.12 Bn
7 Amgen 249.20 Bn 200.85 Bn 7.58 Bn 3.86 Bn
8 Gilead Sciences 207.48 Bn 182.59 Bn 6.73 Bn 2.43 Bn
9 Pfizer 167.49 Bn 114.85 Bn 12.56 Bn 3.24 Bn
10 Vertex Pharmaceuticals 138.73 Bn 110.72 Bn 2.91 Bn 653.60 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 27, 2026 210.00 Mn
Jun 28, 2026 5.53 Bn
Mar 29, 2026 5.24 Bn
Dec 28, 2025 5.12 Bn
Sep 28, 2025 5.15 Bn
Jun 29, 2025 5.54 Bn
Mar 30, 2025 11.00 Bn
Dec 29, 2024 3.43 Bn
Sep 29, 2024 2.69 Bn
Jun 30, 2024 4.69 Bn
Mar 31, 2024 3.26 Bn
Dec 31, 2023 4.05 Bn
Oct 1, 2023 26.03 Bn
Jul 2, 2023 5.14 Bn
Apr 2, 2023 -68.00 Mn
Jan 1, 2023 3.52 Bn
Oct 2, 2022 4.46 Bn
Jul 3, 2022 4.81 Bn
Apr 3, 2022 5.15 Bn
Oct 3, 2021 3.67 Bn
API Access

Johnson & Johnson Net Income towards Common Stockholders API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=JNJ&period=max&api_key=YOUR_API_KEY